MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.alit.2024.02.002

Медицинская библиотека · Allergology international : official journal of the Japanese Society of Allergology · 2024

Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study.

Tajiri Tomoko, Suzuki Motohiko, Nishiyama Hirono, Ozawa Yoshiyuki, Kurokawa Ryota, Takeda Norihisa, Ito Keima, Fukumitsu Kensuke, Kanemitsu Yoshihiro, Mori Yuta, Fukuda Satoshi, Uemura Takehiro, Ohkubo Hirotsugu, Takemura Masaya, Maeno Ken, Ito Yutaka, Oguri Tetsuya, Izuhara Kenji, Niimi Akio

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Dupilumab has clinical effects in patients with moderate-to-severe asthma. When considering interleukin (IL)-4 and IL-13 signaling, effects of dupilumab on airway mucus hypersecretion and airway remodeling are expected, but they have been reported in only a few short-term studies. Its efficacy for airway hyperresponsiveness (AHR) remains unknown. We comprehensively assessed the efficacy of dupilumab, especially for subjective and objective measures of airway mucus hypersecretion and airway dimensions in moderate-to-severe asthmatic patients.

METHODS

In 28 adult patients with moderate-to-severe uncontrolled asthma, the comprehensive efficacy of 48-week dupilumab treatment, including the Cough and Sputum Assessment Questionnaire (CASA-Q), radiological mucus scores and airway dimensions on computed tomography (CT), was assessed prospectively. Treatment responsiveness to dupilumab was analyzed.

RESULTS

With 48-week dupilumab treatment, all four cough and sputum domain scores of CASA-Q improved significantly. Radiological mucus scores and airway wall thickening on CT were significantly decreased. The decreases in mucus scores were significantly associated with improvements in Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire (AQLQ) overall scores, airway obstruction, and airway type 2 inflammation. When defined by > 0.5 improvement in AQLQ overall scores, 18 patients (64%) were identified as responders.

CONCLUSIONS

Dupilumab reversed subjective and objective measures of airway mucus hypersecretion and some aspects of airway remodeling in patients with moderate-to-severe uncontrolled asthma.

Для цитирования: Tajiri Tomoko, Suzuki Motohiko, Nishiyama Hirono, Ozawa Yoshiyuki, Kurokawa Ryota, Takeda Norihisa, Ito Keima, Fukumitsu Kensuke, Kanemitsu Yoshihiro, Mori Yuta, Fukuda Satoshi, Uemura Takehiro, Ohkubo Hirotsugu, Takemura Masaya, Maeno Ken, Ito Yutaka, Oguri Tetsuya, Izuhara Kenji, Niimi Akio. Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: A prospective, observational study.. Allergology international : official journal of the Japanese Society of Allergology. 2024. DOI: 10.1016/j.alit.2024.02.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.